Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease

Neurosci Lett. 2023 Mar 28:801:137140. doi: 10.1016/j.neulet.2023.137140. Epub 2023 Feb 21.

Abstract

Introduction: Levodopa-induced dyskinesia (LID) is a common motor complication in Parkinson's disease (PD). Several genes in the levodopa metabolic pathway, such as COMT, DRDx and MAO-B, were reported associated with LID. However, there has been no systematic analyses between common variants in levodopa metabolic pathway genes and LID in a large sample of the Chinese population.

Methods: Through the whole exome sequencing (WES) and target region sequencing, we aimed to explore the potential associations between common single nucleotide polymorphisms (SNPs) in the levodopa metabolic pathway and LID in Chinese PD individuals. Five hundred and two PD individuals were enrolled in our study, among them, 348 individuals underwent WES, and 154 individuals underwent target region sequencing. We acquired the genetic profile of 11 genes including COMT, DDC, DRD1-5, SLC6A3, TH and MAO-A/B. We established a stepwise strategy to filter SNPs, which finally included 34 SNPs in our analyses. And we used a two-stage study, with discovery (348 individuals with WES) and the replication (all 502 individuals) to confirm our findings.

Results: Among the 502 PD individuals, 104 (20.7%) were diagnosed with LID. In the discovery stage, we found that COMT rs6269, DRD2 rs6275 and DRD2 rs1076560 were associated with LID. In the replication stage, associations between the three above-mentioned SNPs and LID were still present in all 502 individuals.

Conclusion: We demonstrated that in the Chinese population, COMT rs6269, DRD2 rs6275 and rs1076560 were significantly associated with LID. And rs6275 was reported associated with LID for the first time.

Keywords: COMT; DRD2; Dyskinesia; Parkinson’s disease; SNPs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparkinson Agents / adverse effects
  • Dyskinesia, Drug-Induced* / genetics
  • Humans
  • Levodopa / adverse effects
  • Monoamine Oxidase / genetics
  • Parkinson Disease* / drug therapy
  • Parkinson Disease* / genetics
  • Polymorphism, Single Nucleotide

Substances

  • Levodopa
  • Antiparkinson Agents
  • Monoamine Oxidase